Revaprazan hydrochloride 是一种新型酸泵拮抗剂 (APA)。 Revaprazan hydrochloride 可降低 COX-2 的表达，并在幽门螺杆菌感染中具有显着的抗炎作用。 Information Revaprazan Hydrochloride Revaprazan Hydrochloride (YH1885) is a new reversible proton pump inhibitor with long-lasting acid-suppressive effects. Revaprazan Hydrochloride reversibly inhibits H(+)/K(+)-ATPase via binding to the K+-binding site of the pump. Targets Proton pump ; H(+)/K(+)-ATPase In vitro Revaprazan Hydrochloride reversibly inhibits H+/K+-ATPase via binding to the K+-binding site of the pump. This reversibility leads to fewer adverse events. Revaprazan could inhibit H.pylori-induced COX-2 expression by blocking phosphorylation of IκB-α and Akt signaling in AGS cells. It could impose significant anti-inflammatory actions on H.pylori infection beyond acid suppression. In vivo Pharmacokinetic studies of revaprazan hydrochloride in rats and dogs showed the drug had a low oral bioavailability, which was speculated to be due to first pass effect and poor water solubility of drug. Cell Research(from reference) Cell lines：AGS cells, human gastric adenocarcinoma epithelial cell Concentrations：5, 20, 50 μM Incubation Time：2 h